The role of empagliflozin in the management of type 2 diabetes by patient profile.

about

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.

P2860

Q36402095-01EEDF21-DF43-4E18-81EA-38D07B2B8996

P2860

The role of empagliflozin in the management of type 2 diabetes by patient profile.

Item

http://www.wikidata.org/entity/Q35592873

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The role of empagliflozin in the management of type 2 diabetes by patient profile.

@ast

The role of empagliflozin in the management of type 2 diabetes by patient profile.

@en

type

Item

label

The role of empagliflozin in the management of type 2 diabetes by patient profile.

@ast

The role of empagliflozin in the management of type 2 diabetes by patient profile.

@en

prefLabel

The role of empagliflozin in the management of type 2 diabetes by patient profile.

@ast

The role of empagliflozin in the management of type 2 diabetes by patient profile.

@en

P1476

The role of empagliflozin in the management of type 2 diabetes by patient profile.

@en

P2093

Maka S Hedrington

http://www.w3.org/2001/XMLSchema#string

Stephen N Davis

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Active sugar transport in health and disease

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.

P304

739-749

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S71762

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277080209

http://www.w3.org/2001/XMLSchema#string

P698

25999725

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4427256

http://www.w3.org/2001/XMLSchema#string

The role of empagliflozin in the management of type 2 diabetes by patient profile.

about

P2860

P2860

The role of empagliflozin in the management of type 2 diabetes by patient profile.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932